Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives

被引:1
|
作者
Han, Sanghoon [1 ]
Bommireddy, Ramireddy [1 ,2 ,3 ]
Kim, Pauline [1 ,4 ]
Selvaraj, Periasamy [1 ,2 ]
Shin, Dong M. [1 ,3 ]
机构
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[4] Emory Univ Hosp Midtown, Dept Pharmaceut Serv, Atlanta, GA USA
关键词
GROWTH-FACTOR-RECEPTOR; SQUAMOUS-CELL CARCINOMA; LOW-DOSE ISOTRETINOIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 2ND PRIMARY TUMORS; GREEN TEA EXTRACT; RETINOIC ACID; PHOTODYNAMIC THERAPY; SIGNALING PATHWAYS; ORAL-CANCER;
D O I
10.1158/1940-6207.CAPR-24-0093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Head and neck squamous cell carcinoma (HNSCC) is a spectrum of heterogeneous malignancies. A variety of genetic, environmental, and lifestyle factors contribute to the development of HNSCC. Carcinogenesis is a multistep process in which cell proliferation-associated oncogenes and cell-cycle regulation-associated tumor suppressor genes are dysregulated, resulting in premalignant lesions. Immune evasion is a critical step in the progression of benign lesions to advanced cancer. This review discusses the advances that have been made in chemoprevention strategies for HNSCC. The rationale for the use of chemopreventive agents to inhibit head and neck cancer development is highlighted by the positive outcomes of several clinical trials. We discuss the potential of some of the commonly studied agents including vitamin A analogs, EGFR inhibitors, COX-2 inhibitors, metabolic modulators, and natural compounds such as green tea, as well as immunotherapy and photodynamic therapy to prevent HNSCC. Our review provides insight into the potential benefits of these agents and the gaps that remain to be addressed. The published results reaffirm the promise of chemoprevention in head and neck cancer and suggest that continued exploration is needed to overcome the limitations. Because the current focus on chemopreventive agents is limited, major efforts in precision oncology approaches and substantial increase in funding will promote research into chemoprevention, which will eventually decrease the incidence of HNSCC.
引用
收藏
页码:443 / 455
页数:13
相关论文
共 50 条
  • [21] The Current State of Head and Neck Cancer Gene Therapy
    Thomas, Sufi Mary
    Grandis, Jennifer Rubin
    HUMAN GENE THERAPY, 2009, 20 (12) : 1565 - 1575
  • [22] Lung cancer chemoprevention: current status and future prospects
    Keith, Robert L.
    Miller, York E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) : 334 - 343
  • [23] Chemopreventive Potential of Natural Compounds in Head and Neck Cancer
    Rahman, Mohammad Aminur
    Amin, A. R. M. Ruhul
    Shin, Dong M.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2010, 62 (07): : 973 - 987
  • [24] Approaches for Head and Neck Cancer Research - Current Status and the Way Forward
    Barghavi, V.
    Femina, T. Arokia
    Iyengar, DivyaSowrirajan
    Archana, K.
    Ravi, Maddaly
    CANCER INVESTIGATION, 2022, 40 (02) : 151 - 172
  • [25] Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer
    Tathineni, Praveena
    Joshi, Nikhil
    Jelinek, Michael J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 680 - 692
  • [26] Current Role of Dacomitinib in Head and Neck Cancer
    Elicin, Olgun
    Ozsahin, Mahmut
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (06) : 735 - 742
  • [27] Molecular margins in head and neck cancer: Current techniques and future directions
    Stepan, Katelyn O.
    Li, Michael M.
    Kang, Stephen Y.
    Puram, Sidharth, V
    ORAL ONCOLOGY, 2020, 110
  • [28] Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions
    Enokida, Tomohiro
    Tahara, Makoto
    CANCERS, 2021, 13 (06) : 1 - 20
  • [29] Current relevance of hypoxia in head and neck cancer
    Bredell, Marius G.
    Ernst, Jutta
    El-Kochairi, Ilhem
    Dahlem, Yuliya
    Ikenberg, Kristian
    Schumann, Desiree M.
    ONCOTARGET, 2016, 7 (31) : 50781 - 50804